Vincent Milano

Filings by Vincent Milano span 5 companies, the busiest being Biocryst Pharmaceuticals Inc, Idera Pharmaceuticals, Inc. and Aclaris Therapeutics, Inc. Between 15 March 2016 and 11 June 2026, the trades on record add up to 43 filings.

The open-market side counts 5 purchases for €325k alongside 4 sales for €142k. Netting one side against the other leaves €182k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 26 share grants and 7 option exercises.

A typical purchase (the median) is worth €71k. Clusters matter here: 4 out of 5 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 15 June 2026 with a share grant in Biocryst Pharmaceuticals Inc. The most recent open-market purchase was published on 22 May 2024, 882 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.